---
title: "CareDx, Inc. (CDNA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CDNA.US.md"
symbol: "CDNA.US"
name: "CareDx, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T12:35:18.996Z"
locales:
  - [en](https://longbridge.com/en/quote/CDNA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CDNA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CDNA.US.md)
---

# CareDx, Inc. (CDNA.US)

## Company Overview

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [caredx.com](https://caredx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.41)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 107 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 19.17% |  |
| Net Profit YoY | -113.20% |  |
| P/B Ratio | 3.38 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1060569144.93 |  |
| Revenue | 412820000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -2.36% | D |
| Profit Margin | -1.98% | D |
| Gross Margin | 71.43% | A |
| Revenue YoY | 19.17% | B |
| Net Profit YoY | -113.20% | E |
| Total Assets YoY | -16.05% | E |
| Net Assets YoY | -17.35% | E |
| Cash Flow Margin | -890.49% | E |
| OCF YoY | 19.17% | B |
| Turnover | 0.92 | A |
| Gearing Ratio | 23.73% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CareDx, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "19.17%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-113.20%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.38",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1060569144.93",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "412820000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-2.36%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-1.98%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "71.43%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "19.17%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-113.20%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-16.05%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-17.35%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-890.49%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "19.17%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.92",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "23.73%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -129.46 | 546/386 | 15.21 | 13.73 | 12.17 |
| PB | 3.38 | 272/386 | 3.26 | 2.84 | 2.36 |
| PS (TTM) | 2.57 | 66/386 | 2.88 | 2.54 | 2.24 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-30T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 43% |
| Hold | 4 | 57% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 20.53 |
| Highest Target | 28.00 |
| Lowest Target | 21.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CDNA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CDNA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CDNA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CDNA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**